HPV Centralized R/R RCT #2 - New York State
NCT03294551 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 37003
Last updated 2021-05-27
Summary
The work done in this trial builds off of the work previously conducted by this same research group in clinicaltrials.gov ID: NCT03057379. Due to some changes in study design, protocol, and cohort of interest, a new registration was warranted.
The overarching goal of this study is to evaluate the effectiveness, cost-effectiveness, and sustainability of utilizing statewide immunization information systems (IISs) to conduct centralized reminder recall (R/R) to improve human papillomavirus (HPV) vaccination rates among adolescents 11-14 years of age.
The latest recommendations from the ACIP, as of February 2017, modified the vaccination schedule for the HPV series for eligible adolescents ages 11-14. Adolescents who receive dose #1 between the ages of 11 and 14 are now eligible for their second and final dose 6-12 months after their initial dose. Despite U.S. guidelines for vaccinating all adolescents starting at age 11 with the HPV vaccine, in 2012 only 53% of 13-17 year old females had \>1 dose and 35% had 3 doses; 21% of teen males had a vaccination. Modeling studies predict marked reduction in HPV associated cancers and in disparities in these cancers if high HPV vaccination rates can be achieved.
With this new dosing schedule for adolescents, the research team proposes to conduct a randomized control trial (RCT) utilizing the capabilities of the State Immunization Information System (IIS), and create a HPV-specific R/R autodialer and text message to be delivered to the parents of patients ages 11-14 of randomly selected practices within New York State (excluding NYC). Upon conclusion of this trial, researchers will develop a toolkit for dissemination so that other state IIS systems may replicate these centralized reminder recall procedures.
Conditions
- Vaccines
Interventions
- BEHAVIORAL
-
HPV Vaccine Reminder Recall - Autodialer
Investigators will send out HPV vaccine reminder recall notices via autodialer message to the parents of adolescents 11-14 years of age who are eligible to receive a dose of the HPV vaccine per the records in the New York State Immunization Information System (NYSIIS). The investigators will be testing the effectiveness and cost effectiveness of the various modalities or reminders as compared to the standard of care control (no reminders)
- BEHAVIORAL
-
HPV Vaccine Reminder Recall - Texting
Investigators will send out HPV vaccine reminder recall notices via text message to the parents of adolescents 11-14 years of age who are eligible to receive a dose of the HPV vaccine per the records in the New York State Immunization Information System (NYSIIS). The investigators will be testing the effectiveness and cost effectiveness of the various modalities or reminders as compared to the standard of care control (no reminders)
Sponsors & Collaborators
-
National Cancer Institute (NCI)
collaborator NIH -
University of Colorado, Denver
collaborator OTHER -
New York State Department of Health
collaborator OTHER_GOV -
University of California, Los Angeles
lead OTHER
Principal Investigators
-
Peter Szilagyi, MD MPH · University of California, Los Angeles
Study Design
- Allocation
- RANDOMIZED
- Purpose
- HEALTH_SERVICES_RESEARCH
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 11 Years
- Max Age
- 14 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-10-27
- Primary Completion
- 2019-11-05
- Completion
- 2019-11-05
Countries
- United States
Study Locations
More Related Trials
-
Human Papilloma Viruses (HPV) Vaccine Adherence Community Clinic Study
NCT01908517 ·Status: COMPLETED ·Phase: NA
-
Impact of Adolescent Vaccine Reminder Notices Sent Via Preferred Method of Communication on HPV Vaccination
NCT05148559 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3
NCT02558803 ·Status: COMPLETED ·Phase: NA
-
The HPV 9-10 Trial: Early Initiation of HPV Vaccination
NCT04722822 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
The STOP-HPV Trial 1: Communication Intervention
NCT03599557 ·Status: COMPLETED ·Phase: NA
-
The STOP-HPV Trial 3: Prompts Intervention
NCT03599583 ·Status: UNKNOWN ·Phase: NA
-
Electronic Messaging to Increase Human Papillomavirus Vaccine Utilization and Adherence Among College Students
NCT01568515 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Usability of HPV Vaccine Reminders
NCT03987490 ·Status: COMPLETED ·Phase: NA
-
The STOP-HPV Trial 2: Performance Feedback Intervention
NCT03599570 ·Status: COMPLETED ·Phase: NA
-
Maximizing HPV Vaccination: Real-time Reminders, Guidance, and Recommendations - Part 4: Feasibility Trial
NCT03429413 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Facilitating Completion of HPV Vaccination
NCT01600560 ·Status: COMPLETED
-
Innovative Tool to Increase Completion of Human Papillomavirus (HPV) Vaccine Series
NCT01343485 ·Status: COMPLETED ·Phase: NA
-
Educational Intervention to Minimize Disparities in Humanpapillomavirus Vaccination
NCT02145156 ·Status: COMPLETED ·Phase: NA
-
Text and Talk: A Multi-level Intervention to Increase Provider HPV Vaccine Recommendation Effectiveness
NCT05006833 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
PREVENT Pilot HPV - Related Cancers Trial
NCT06738355 ·Status: COMPLETED ·Phase: NA
-
Increasing Human Papillomavirus (HPV) Vaccine Uptake Via General Health Messaging
NCT03759236 ·Status: COMPLETED ·Phase: NA
-
The STOP-HPV Trial 4: Bundle Intervention
NCT03609242 ·Status: UNKNOWN ·Phase: NA
-
Tailoring of Vaccine-Focused Messages: Disease Salience
NCT03002324 ·Status: COMPLETED ·Phase: NA
-
Recombinant Human Papillomavirus Nonavalent Vaccine in Preventing Human Papilloma Virus in Younger Healthy Participants
NCT02568566 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Developing a Self-persuasion Intervention Promoting Adolescent HPV Vaccination: Feasibility Trial
NCT02535845 ·Status: TERMINATED ·Phase: NA
-
Gardasil Administration
NCT03123419 ·Status: WITHDRAWN ·Phase: NA
-
AFIX to Improve HPV Vaccination
NCT02370459 ·Status: COMPLETED ·Phase: NA
-
Clinical Trial Evaluating Secondary HPV Vaccination After Treatment of High-grade Cervical Lesions
NCT06658405 ·Status: RECRUITING ·Phase: PHASE2
-
Alternate Dosing Schedules Study for HPV Vaccine (ADS)
NCT02280642 ·Status: COMPLETED
-
An Evaluation of Tailored Messages to Address Parental Questions About HPV Vaccination
NCT03628885 ·Status: COMPLETED ·Phase: NA